Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government
Aug. 21, 2018
SYDNEY, Australia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has received a €1,221,906 (~ A$1,910,010) cash rebate from the French Government under its Crédit d’Impôt Recherche scheme (CIR).
The “Crédit d’Impôt Recherche” (CIR), meaning “Research Tax Credit”, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
Immutep qualifies to receive CIR credits through its subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory at Châtenay-Malabry in southwestern Paris.
The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Further information can be found on the Company’s website www.immutep.com or by contacting:
U.S. Investors:Jay Campbell, Vice President of Business Development and Investor Relations, Immutep Limited+1 (917) 860-9404; email@example.com
Garth Russell, LifeSci Advisors +1 (646) 876-3613; firstname.lastname@example.org
Australian Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2 8234 0105; email@example.com